{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VX-661%2FIvacaftor", "query": { "intervention": "VX-661/Ivacaftor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VX-661%2FIvacaftor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T08:14:36.129Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03537651", "title": "A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 130, "start_date": "2018-04-25", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03537651" }, { "nct_id": "NCT02951195", "title": "A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-152", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2016-11", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2021-01-28", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951195" }, { "nct_id": "NCT04183790", "title": "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 64, "start_date": "2020-02-17", "completion_date": "2024-02-24", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 13, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04183790" }, { "nct_id": "NCT03525444", "title": "A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-445/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 405, "start_date": "2018-06-15", "completion_date": "2019-04-24", "has_results": true, "last_update_posted_date": "2020-05-19", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 53, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03525444" }, { "nct_id": "NCT03624101", "title": "Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Symdeko", "type": "DRUG" }, { "name": "Ivacaftor and Symdeko", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-12-01", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2025-04-16", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03624101" }, { "nct_id": "NCT02516410", "title": "A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-661 plus ivacaftor combination", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Placebo (matched to VX-661 plus ivacaftor combination)", "type": "DRUG" }, { "name": "Placebo (matched to ivacaftor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 168, "start_date": "2015-08", "completion_date": "2016-06-07", "has_results": true, "last_update_posted_date": "2018-06-12", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 22, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02516410" }, { "nct_id": "NCT04043806", "title": "A Study Evaluating the Long-term Safety of VX-445 Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 458, "start_date": "2019-08-09", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04043806" }, { "nct_id": "NCT04058353", "title": "A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 271, "start_date": "2019-08-28", "completion_date": "2020-06-12", "has_results": true, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04058353" }, { "nct_id": "NCT02953314", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TEZ", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 83, "start_date": "2016-11", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953314" }, { "nct_id": "NCT04509050", "title": "Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor or elexacaftor/tezacaftor/ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sonya Heltshe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "10 Years", "sex": "ALL", "summary": "Up to 10 Years" }, "enrollment_count": 210, "start_date": "2020-11-18", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-29T08:14:36.129Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04509050" } ] }